IP Library › Granted Patent US 12,594,285
Granted Patent B2
US 12,594,285 · App. 17/497,813 · Granted Apr 7, 2026

Compositions and methods for protecting against airborne pathogens and irritants

Inventor: Nazlie Latefi (New York, NY)
Assignee: APPLIED BIOLOGICAL LABORATORIES, INC.
A61K31/7012A61K9/0019A61K9/0043A61K9/0073A61K31/352A61K31/7016A61K33/30A61K33/34A61K33/38A61K36/28A61K36/328A61K36/53A61K36/752A61K38/1774A61K38/40A61K38/47A61K45/06A61K47/10A61K47/26A61K47/44A61P11/00A61P31/00C12Y302/01017C12N9/24C12N2760/16263
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,594,285
App. No.
17/497,813
Granted
Apr 7, 2026
Kind
B2
Abstract

The present disclosure features methods and compositions for enhancing the ability of the respiratory membranes to filter airborne pathogens and protect a subject from respiratory infections that result from inhalation or ingestion of such pathogens. In particular, the disclosure provides antimicrobial compositions that prevent and treat respiratory infections caused by bacteria, fungi, and viruses.

Claims (13)

1 . A method of protecting the epithelial and mucous membranes of a subject from viral respiratory infection comprising administration of a pharmaceutical composition to the subject having a residence time on the oral mucosa of at least 5 minutes, wherein said pharmaceutical composition comprises a pharmaceutically acceptable carrier and:

a) lysozyme; and

b) lactoferrin,

the pharmaceutical composition is in the form of a nasal spray, oral spray, oral rinse, or lozenge, and said composition is isotonic to the nasal epithelia or mucous membrane;

wherein administration of the pharmaceutical composition to the subject inhibits the viral respiratory infection on the epithelial and/or mucous membranes,

a weight ratio of lactoferrin:lysozyme of about 1:4 to about 1:25.

2 . The method according to claim 1 , wherein the viral respiratory infection is rhinovirus or influenza.

3 . The method according to claim 1 , wherein the pharmaceutical composition further comprises sialic acid and/or soluble ICAM-1.

4 . The method according to claim 1 , wherein the pharmaceutical composition is in the form of a lozenge.

5 . The method according to claim 1 , wherein the carrier at 25° C. has the Hansen Solubility Parameters of an energy from dispersion (δ d ) of between about 15 and about 18, an energy from dipolar intermolecular force between molecules (δ p ) of between about 15 and about 15, and energy from hydrogen bonds (δ h ) of between about 21 and about 25.

6 . The method according to claim 5 , wherein the pharmaceutically acceptable carrier comprises a mixture of water and propanediol or a mixture of water and glycerin.

7 . The method according to claim 1 , wherein the weight ratio of lactoferrin to lysozyme is from 1:5 to 1:20.

8 . The method according to claim 1 , wherein the composition does not comprise carrageenan.

Assignments (3)
SECURITY INTEREST Recorded Mar 4, 2026
From: APPLIED BIOLOGICAL LABORATORIES INC.
To: TRANSMINEO LLC
Reel/Frame 074779/0590 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2024
From: LATEFI, NAZLIE, MRS.
To: APPLIED BIOLOGICAL LABORATORIES, INC.
Reel/Frame 068129/0050 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2024
From: LATEFI, NAZLIE
To: APPLIED BIOLOGICAL LABORATORIES, INC.
Reel/Frame 067057/0467 →
Continuity (4)
Continuation 15691648 · Aug 30, 2017
Continuation In Part 15442604 · Feb 24, 2017
Provisional Application 62299775 · Feb 25, 2016
Related Publication 20220047614A1 · Feb 17, 2022
References Cited (99)
US 2156254A · Manchey · 1939 [cited by examiner]
US 4734729A · Wolfgang et al. · 1988 [cited by applicant]
US 5576299A · Ando et al. · 1996 [cited by applicant]
US 5993089A · Weaver et al. · 1999 [cited by applicant]
US 6020333A · Berque · 2000 [cited by applicant]
US 6093417A · Petrus · 2000 [cited by applicant]
US 6183742B1 · Kiczka · 2001 [cited by applicant]
US 6329339B1 · Pompei et al. · 2001 [cited by applicant]
US 6365156B1 · Lee · 2002 [cited by applicant]
US 6503881B2 · Krieger et al. · 2003 [cited by applicant]
US 6716813B2 · Lim et al. · 2004 [cited by applicant]
US 7459283B2 · Wertz et al. · 2008 [cited by applicant]
US 7662607B2 · Wang et al. · 2010 [cited by applicant]
US 7846430B2 · Ferrari · 2010 [cited by applicant]
US 7989003B2 · Hensley et al. · 2011 [cited by applicant]
US 8263138B2 · Perraudin · 2012 [cited by applicant]
US 20030134779A1 · Diarra et al. · 2003 [cited by applicant]
US 20030219402A1 · Rutter · 2003 [cited by applicant]
US 20040063617A1 · Huang · 2004 [cited by examiner]
US 20050158327A1 · Mohapatra et al. · 2005 [cited by applicant]
US 20050245467A1 · Berg · 2005 [cited by applicant]
US 20060159671A1 · Fischetti · 2006 [cited by applicant]
US 20070116750A1 · Wolcott · 2007 [cited by applicant]
US 20090142298A1 · Shatunovskiy · 2009 [cited by applicant]
US 20100143490A1 · Roberts et al. · 2010 [cited by applicant]
US 20100160245A1 · Lines · 2010 [cited by applicant]
US 20100209419A1 · Bhushan · 2010 [cited by examiner]
US 20100233129A1 · Fichot · 2010 [cited by applicant]
US 20110015120A1 · Bortolin · 2011 [cited by applicant]
US 20110052727A1 · Polansky · 2011 [cited by applicant]
US 20110059919A1 · Grassauer et al. · 2011 [cited by applicant]
US 20110301077A1 · Perraudin · 2011 [cited by applicant]
US 20120171164A1 · Wittke et al. · 2012 [cited by applicant]
US 20130028882A1 · Colman · 2013 [cited by examiner]
US 20130034542A1 · Ganter et al. · 2013 [cited by applicant]
US 20130058912A1 · Griswold et al. · 2013 [cited by applicant]
US 20130309220A1 · Matalon · 2013 [cited by applicant]
US 20140121237A1 · Tripp et al. · 2014 [cited by applicant]
US 20150093371A1 · Colman et al. · 2015 [cited by applicant]
US 20160022713A1 · Wang et al. · 2016 [cited by applicant]
US 20160144004A1 · Pellico · 2016 [cited by applicant]
US 20170065720A1 · Nguyen et al. · 2017 [cited by applicant]
US 20170246262A1 · Latefi · 2017 [cited by applicant]
US 20170360815A1 · Latefi · 2017 [cited by examiner]
CN 1248603A · 2000 [cited by applicant]
CN 1679926A · 2005 [cited by applicant]
CN 101190331A · 2008 [cited by applicant]
CN 100493605C · 2009 [cited by applicant]
CN 101947278A · 2011 [cited by applicant]
EP 2845606A1 · 2015 [cited by applicant]
GB 981260A1 · 1965 [cited by applicant]
GB 1171183A · 1969 [cited by applicant]
GB 1174187A · 1969 [cited by applicant]
GB 1431709 · 1976 [cited by applicant]
GB 2374008A · 2002 [cited by applicant]
JP 2001525814A · 2001 [cited by applicant]
JP 2009102370A · 2009 [cited by applicant]
JP 2013515022A · 2013 [cited by applicant]
KR 20100132737A · 2010 [cited by applicant]
KR 101119538B1 · 2012 [cited by applicant]
KR 20120065654A · 2012 [cited by applicant]
RU 2504396C1 · 2014 [cited by applicant]
RU 2535053C2 · 2014 [cited by applicant]
RU 2548803C2 · 2015 [cited by applicant]
WO 9527736A1 · 1995 [cited by applicant]
WO 1998006425A1 · 1998 [cited by applicant]
WO WO0032171A2 · 2000 [cited by examiner]
WO 2001092336A1 · 2001 [cited by applicant]
WO 2003051281A3 · 2003 [cited by applicant]
WO 2006028497A2 · 2006 [cited by applicant]
WO WO2009009156A2 · 2009 [cited by examiner]
WO 2011130799A1 · 2011 [cited by applicant]
WO 2012022734A2 · 2012 [cited by applicant]
WO 2014151523A1 · 2014 [cited by applicant]
WO WO15092041A1 · 2015 [cited by applicant]
WO 2017147540A1 · 2017 [cited by applicant]
Miriam Kuipers, et al., Design and Fungicidal Activity of Mucoadhesive Lactoferrin Tablets for the Treatment of Oropharyngeal Candidosis, 9 Drug Delivery 31 (Year: 2002). [cited by examiner]
Gabriella Cisani, et al, Inhibition of Herpes Simplex Virus-Induced Cytopathic Effect by Modified Hen Egg-white Lysozymes, 10 Curr. Microbiol. 35 (Year: 1984). [cited by examiner]
Abstract—44th Annual Meeting of the Brazilian Society for Biochemistry and Molecular Biology, Aug. 2015, p. 1 (Year: 2015). [cited by examiner]
Abouhmad et al., “T4 Iysozyme fused with cellulos-binding module for antimicrobial cellulosic wound dressing materials,” Journal of Applied Microbiology, vol. 121, pp. 115-125 (2016). [cited by applicant]
International Search Report and Written Opinion to corresponding International Application No. PCT/US2017/019535 mailed May 8, 2017 (12 pages). [cited by applicant]
Lei et al., “Dynamic Spongy Microporous Films to Load Lysozyme for Antibacterial Coating,” Acta Polymerica Sinica, No. 5, pp. 744-751 (2017). [cited by applicant]
Marlin et al., “A Soluble Form of Intercellular Adhesion Molecule—1 Inhibits Rhinovirus Infection,” Nature; London, vol. 344, No. 6261, pp. 70-72 (1990). [cited by applicant]
Muscedere et al., “Prevention of nosocomial infections in critically ill patients with lactoferrin (Prevail study): study protocol for a randomized controlled trial,” Trials, vol. 17, No. 474 (2016). [cited by applicant]
Pammi et al., “Oral lactoferrin for the treatment of sepsis and necrotizing enterocolitis in neonates (Review),” Issue 10, 14 pages (2011). [cited by applicant]
Samaranayake et al., “Synergistic activity of lysozyme and antifungal agents against Candida albicans biofilms on denture acrylic surfaces,” ScienceDirect, vol. 54, pp. 115-126 (2009). [cited by applicant]
Turner et al., “Efficacy of Tremacamra, a Soluble Intercellular Adhesion Molecule 1, for Experimental Rhinovirus Infection: A randomized Clinical Trial,” JAMA, May 19, 1999, vol. 281, No. 19, pp. 1797-1804. [cited by applicant]
Search Report and Written Opinion in corresponding Singapore Patent Application No. 11201806868T, dated Nov. 28, 2019 (13 pages). [cited by applicant]
Search Report for corresponding Russian Patent Application No. 2018133581 (2 pages). [cited by applicant]
Office Action for corresponding Russian Patent Application No. 2018133581, issued on Aug. 11, 2020 (5 pages. [cited by applicant]
Yulish, et al., “Factors of immunity in respiratory infections and methods for their activating in aid of a pediatrist,” 2010, vol. 5, No. 6, pp. 63-67 (English Abstract). [cited by applicant]
First Examination Report for corresponding Indian Application No. 201817032360, dated Jun. 25, 2020 (6 pages). [cited by applicant]
Wakabayashi et al., “Lactoferrin for prevention of common viral infections,” Journal of Infection and Chemotherapy, Aug. 30, 2014, vol. 20, 666-671. [cited by applicant]
Al-Nabulsi et al., “Enhancing the antimicrobial effects of bovine lactoferrin against [cited by applicant]
Davis et al., “Quercetin reduces susceptibility to influenza infection following stressful exercise,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, Aug. 1, 2008, vol. 295 R505-R509. [cited by applicant]
Kim et al., Inhibition of influenza virus replication by plant-derived isoquercetin, Antiviral Research, Aug. 31, 2010, vol. 88, 227-235. [cited by applicant]
Martin Koenighofer et al: “Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials”, Multidisciplinary Respiratory Medicine, Biomed Central Ltd, Londo… [cited by applicant]
Jefferson Tom: “Advances in the diagnosis and management of influenza”, Current Infectious Disease Reports, Current Science, Philadelphia, PA, US, vol. 4, No. 3, May 1, 2002 (May 1, 2002), pp. 206-210. [cited by applicant]
Schiller, L., “Osmotic Effects of Polyethylene Glycol,” Gastroenterology, vol. 94, No. 4, p. 933-941. Apr. 1988. [cited by applicant]